Skip to main content
Top
Gepubliceerd in:

26-05-2018

Engaging patients and caregivers in prioritizing symptoms impacting quality of life for Duchenne and Becker muscular dystrophy

Auteurs: Ilene L. Hollin, Holly Peay, Ryan Fischer, Ellen M. Janssen, John F. P. Bridges

Gepubliceerd in: Quality of Life Research | Uitgave 9/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Patient preference information (PPI) have an increasing role in regulatory decision-making, especially in benefit–risk assessment. PPI can also facilitate prioritization of symptoms to treat and inform meaningful selection of clinical trial endpoints. We engaged patients and caregivers to prioritize symptoms of Duchenne and Becker muscular dystrophy (DBMD) and explored preference heterogeneity.

Methods

Best–worst scaling (object case) was used to assess priorities across 11 symptoms of DBMD that impact quality of life and for which there is unmet need. Respondents selected the most and least important symptoms to treat among a subset of five. Relative importance scores were estimated for each symptom, and preference heterogeneity was identified using mixed logit and latent class analysis.

Results

Respondents included patients (n = 59) and caregivers (n = 96) affected by DBMD. Results indicated that respondents prioritized “weaker heart pumping” [score = 5.13; 95% CI (4.67, 5.59)] and pulmonary symptoms: “lung infections” [3.15; (2.80, 3.50)] and “weaker ability to cough” [2.65; (2.33, 2.97)] as the most important symptoms to treat and “poor attention span” as the least important symptom to treat [− 5.23; (− 5.93, − 4.54)]. Statistically significant preference heterogeneity existed (p value < 0.001). At least two classes existed with different priorities. Priorities of the majority latent class (80%) reflected the aggregate results, whereas the minority latent class (20%) did not distinguish among pulmonary and other symptoms.

Conclusions

Estimates of the relative importance for symptoms of Duchenne muscular dystrophy indicated that symptoms with direct links to morbidity and mortality were prioritized above other non-skeletal muscle symptoms. Findings suggested the existence of preference heterogeneity for symptoms, which may be related to symptom experience.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Emery, A. E. (2002). The muscular dystrophies. The Lancet, 359(9307), 687–695. Emery, A. E. (2002). The muscular dystrophies. The Lancet, 359(9307), 687–695.
2.
go back to reference Emery, A. E. (1991). Population frequencies of inherited neuromuscular diseases: A world survey. Neuromuscular Disorders, 1(1), 19–29.PubMed Emery, A. E. (1991). Population frequencies of inherited neuromuscular diseases: A world survey. Neuromuscular Disorders, 1(1), 19–29.PubMed
3.
go back to reference Mah, J. K., Korngut, L., Dykeman, J., Day, L., Pringsheim, T., & Jette, N. (2014). A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscular Disorders, 24(6), 482–491.PubMed Mah, J. K., Korngut, L., Dykeman, J., Day, L., Pringsheim, T., & Jette, N. (2014). A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscular Disorders, 24(6), 482–491.PubMed
4.
go back to reference Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., et al. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. The Lancet. Neurology, 9(1), 77–93.PubMed Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., et al. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. The Lancet. Neurology, 9(1), 77–93.PubMed
5.
go back to reference Cyrulnik, S. E., Fee, R. J., Batchelder, A., Kiefel, J., Goldstein, E., & Hinton, V. J. (2008). Cognitive and adaptive deficits in young children with Duchenne muscular dystrophy (DMD). Journal of the International Neuropsychological Society, 14(5), 853–861.PubMed Cyrulnik, S. E., Fee, R. J., Batchelder, A., Kiefel, J., Goldstein, E., & Hinton, V. J. (2008). Cognitive and adaptive deficits in young children with Duchenne muscular dystrophy (DMD). Journal of the International Neuropsychological Society, 14(5), 853–861.PubMed
6.
go back to reference Guglieri, M., Bushby, K., McDermott, M. P., Hart, K. A., Tawil, R., & Martens, W. B. (2017). Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemporary Clinical Trials, 58, 34–39.PubMedPubMedCentral Guglieri, M., Bushby, K., McDermott, M. P., Hart, K. A., Tawil, R., & Martens, W. B. (2017). Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemporary Clinical Trials, 58, 34–39.PubMedPubMedCentral
7.
go back to reference Traynor, K. (2017). Deflazacort approved for Duchenne muscular dystrophy. American Journal of Health-System Pharmacy, 74(6), 368.PubMed Traynor, K. (2017). Deflazacort approved for Duchenne muscular dystrophy. American Journal of Health-System Pharmacy, 74(6), 368.PubMed
8.
go back to reference Aartsma-Rus, A., & Krieg, A. M. (2017). FDA approves Eteplirsen for Duchenne muscular dystrophy: The next chapter in the Eteplirsen saga. Nucleic Acid Therapeutics, 27(1), 1–3.PubMedPubMedCentral Aartsma-Rus, A., & Krieg, A. M. (2017). FDA approves Eteplirsen for Duchenne muscular dystrophy: The next chapter in the Eteplirsen saga. Nucleic Acid Therapeutics, 27(1), 1–3.PubMedPubMedCentral
9.
go back to reference Unger, E. F., & Califf, R. M. (2017). Regarding “Eteplirsen for the treatment of Duchenne muscular dystrophy”. Annals of Neurology, 81(1), 162–164.PubMed Unger, E. F., & Califf, R. M. (2017). Regarding “Eteplirsen for the treatment of Duchenne muscular dystrophy”. Annals of Neurology, 81(1), 162–164.PubMed
10.
go back to reference Niks, E. H., & Aartsma-Rus, A. (2017). Exon skipping: A first in class strategy for Duchenne muscular dystrophy. Expert Opinion on Biological Therapy, 17(2), 225–236.PubMed Niks, E. H., & Aartsma-Rus, A. (2017). Exon skipping: A first in class strategy for Duchenne muscular dystrophy. Expert Opinion on Biological Therapy, 17(2), 225–236.PubMed
12.
13.
go back to reference Woodward, A. T. (2013). A latent class analysis of age differences in choosing service providers to treat mental and substance use disorders. Psychiatric Services, 64(11), 1087–1094.PubMed Woodward, A. T. (2013). A latent class analysis of age differences in choosing service providers to treat mental and substance use disorders. Psychiatric Services, 64(11), 1087–1094.PubMed
14.
go back to reference Wong, Y. N., Egleston, B. L., Sachdeva, K., Eghan, N., Pirollo, M., Stump, T. K., et al. (2013). Cancer patients’ trade-offs among efficacy, toxicity and out-of-pocket cost in the curative and noncurative setting. Medical Care, 51(9), 838–845.PubMed Wong, Y. N., Egleston, B. L., Sachdeva, K., Eghan, N., Pirollo, M., Stump, T. K., et al. (2013). Cancer patients’ trade-offs among efficacy, toxicity and out-of-pocket cost in the curative and noncurative setting. Medical Care, 51(9), 838–845.PubMed
15.
go back to reference Whitty, J. A., Stewart, S., Carrington, M. J., Calderone, A., Marwick, T., Horowitz, J. D., et al. (2013). Patient preferences and willingness-to-pay for a home or clinic based program of chronic heart failure management: Findings from the which? trial. PLoS ONE, 8(3), e58347.PubMedPubMedCentral Whitty, J. A., Stewart, S., Carrington, M. J., Calderone, A., Marwick, T., Horowitz, J. D., et al. (2013). Patient preferences and willingness-to-pay for a home or clinic based program of chronic heart failure management: Findings from the which? trial. PLoS ONE, 8(3), e58347.PubMedPubMedCentral
16.
go back to reference Waschbusch, D. A., Cunningham, C. E., Pelham, W. E. Jr., Rimas, H. L., Greiner, A. R., Gnagy, E. M., et al. (2011). A discrete choice conjoint experiment to evaluate parent preferences for treatment of young, medication naive children with ADHD. Journal of Clinical Child and Adolescent Psychology, 40(4), 546–561.PubMedPubMedCentral Waschbusch, D. A., Cunningham, C. E., Pelham, W. E. Jr., Rimas, H. L., Greiner, A. R., Gnagy, E. M., et al. (2011). A discrete choice conjoint experiment to evaluate parent preferences for treatment of young, medication naive children with ADHD. Journal of Clinical Child and Adolescent Psychology, 40(4), 546–561.PubMedPubMedCentral
17.
go back to reference Naik-Panvelkar, M. P., Armour, C., Rose, J.,M., & Saini, B. (2012). Patient preferences for community pharmacy asthma services. PharmacoEconomics, 30(10), 961–976.PubMed Naik-Panvelkar, M. P., Armour, C., Rose, J.,M., & Saini, B. (2012). Patient preferences for community pharmacy asthma services. PharmacoEconomics, 30(10), 961–976.PubMed
18.
go back to reference Lagarde, M. (2013). Investigating attribute non-attendance and its consequences in choice experiments with latent class models. Health Economics, 22(5), 554–567.PubMed Lagarde, M. (2013). Investigating attribute non-attendance and its consequences in choice experiments with latent class models. Health Economics, 22(5), 554–567.PubMed
19.
go back to reference Guo, N., Marra, C. A., FitzGerald, J. M., Elwood, R. K., Anis, A. H., & Marra, F. (2011). Patient preference for latent tuberculosis infection preventive treatment: A discrete choice experiment. Value in Health, 14(6), 937–943.PubMed Guo, N., Marra, C. A., FitzGerald, J. M., Elwood, R. K., Anis, A. H., & Marra, F. (2011). Patient preference for latent tuberculosis infection preventive treatment: A discrete choice experiment. Value in Health, 14(6), 937–943.PubMed
20.
go back to reference Goossens, L. M., Utens, C. M., Smeenk, F. W., Donkers, B., van Schayck, O. C., & Rutten-van Mölken, M. P. (2014). Should I stay or should I go home? A latent class analysis of a discrete choice experiment on hospital-at-home. Value in Health, 17(5), 588–596.PubMed Goossens, L. M., Utens, C. M., Smeenk, F. W., Donkers, B., van Schayck, O. C., & Rutten-van Mölken, M. P. (2014). Should I stay or should I go home? A latent class analysis of a discrete choice experiment on hospital-at-home. Value in Health, 17(5), 588–596.PubMed
21.
go back to reference Fraenkel, L., Suter, L., Cunningham, C. E., & Hawker, G. (2014). Understanding preferences for disease-modifying drugs in osteoarthritis. Arthritis Care and Research, 66(8), 1186–1192.PubMed Fraenkel, L., Suter, L., Cunningham, C. E., & Hawker, G. (2014). Understanding preferences for disease-modifying drugs in osteoarthritis. Arthritis Care and Research, 66(8), 1186–1192.PubMed
22.
go back to reference Cunningham, C. E., Chen, Y., Deal, K., Rimas, H., McGrath, P., Reid, G., et al. (2013). The interim service preferences of parents waiting for children’s mental health treatment: A discrete choice conjoint experiment. Journal of Abnormal Child Psychology, 41(6), 865–877.PubMed Cunningham, C. E., Chen, Y., Deal, K., Rimas, H., McGrath, P., Reid, G., et al. (2013). The interim service preferences of parents waiting for children’s mental health treatment: A discrete choice conjoint experiment. Journal of Abnormal Child Psychology, 41(6), 865–877.PubMed
23.
go back to reference Carroll, F. E., Al-Janabi, H., Flynn, T., & Montgomery, A. A. (2013). Women and their partners’ preferences for Down’s syndrome screening tests: A discrete choice experiment. Prenatal Diagnosis, 33(5), 449–456.PubMed Carroll, F. E., Al-Janabi, H., Flynn, T., & Montgomery, A. A. (2013). Women and their partners’ preferences for Down’s syndrome screening tests: A discrete choice experiment. Prenatal Diagnosis, 33(5), 449–456.PubMed
24.
go back to reference Brown, D. S., Poulos, C., Johnson, F. R., Chamiec-Case, L., & Messonnier, M. L. (2014). Adolescent girls’ preferences for HPV vaccines: A discrete choice experiment. Advances in Health Economics and Health Services Research, 24, 93–121.PubMed Brown, D. S., Poulos, C., Johnson, F. R., Chamiec-Case, L., & Messonnier, M. L. (2014). Adolescent girls’ preferences for HPV vaccines: A discrete choice experiment. Advances in Health Economics and Health Services Research, 24, 93–121.PubMed
25.
go back to reference Yan, K., Bridges, J. F., Augustin, S., Laine, L., Garcia-Tsao, G., & Fraenkel, L. (2015). Factors impacting physicians decisions to prevent variceal hemorrhage. BMC Gastroenterology, 15, 55.PubMedPubMedCentral Yan, K., Bridges, J. F., Augustin, S., Laine, L., Garcia-Tsao, G., & Fraenkel, L. (2015). Factors impacting physicians decisions to prevent variceal hemorrhage. BMC Gastroenterology, 15, 55.PubMedPubMedCentral
26.
go back to reference Fraenkel, L., Lim, J., Garcia-Tsao, G., Reyna, V., Monto, A., & Bridges, J. F. P. (2016). Variation in treatment priorities for chronic Hepatitis C: A latent class analysis. The Patient, 9(3), 241–249.PubMed Fraenkel, L., Lim, J., Garcia-Tsao, G., Reyna, V., Monto, A., & Bridges, J. F. P. (2016). Variation in treatment priorities for chronic Hepatitis C: A latent class analysis. The Patient, 9(3), 241–249.PubMed
28.
go back to reference Hunter, N. L., O’Callaghan, K. M., & Califf, R. M. (2015). Engaging patients across the spectrum of medical product development: View from the US Food and Drug Administration. Journal of the American Medical Association, 314(23), 2499–2500.PubMed Hunter, N. L., O’Callaghan, K. M., & Califf, R. M. (2015). Engaging patients across the spectrum of medical product development: View from the US Food and Drug Administration. Journal of the American Medical Association, 314(23), 2499–2500.PubMed
29.
go back to reference Ho, M. P., Gonzalez, J. M., Lerner, H. P., Neuland, C. Y., Whang, J. M., McMurry-Heath, M., et al. (2015). Incorporating patient-preference evidence into regulatory decision making. Surgical Endoscopy, 29(10), 2984–2993.PubMed Ho, M. P., Gonzalez, J. M., Lerner, H. P., Neuland, C. Y., Whang, J. M., McMurry-Heath, M., et al. (2015). Incorporating patient-preference evidence into regulatory decision making. Surgical Endoscopy, 29(10), 2984–2993.PubMed
30.
go back to reference Hauber, B. A., Fairchild, A. O., & Johnson, R. F. (2013). Quantifying benefit-risk preferences for medical interventions: An overview of a growing empirical literature. Applied Health Economics and Health Policy, 11(4), 319–329. Hauber, B. A., Fairchild, A. O., & Johnson, R. F. (2013). Quantifying benefit-risk preferences for medical interventions: An overview of a growing empirical literature. Applied Health Economics and Health Policy, 11(4), 319–329.
31.
go back to reference van Til, J. A., & Ijzerman, M. J. (2014). Why should regulators consider using patient preferences in benefit-risk assessment? PharmacoEconomics, 32(1), 1–4.PubMed van Til, J. A., & Ijzerman, M. J. (2014). Why should regulators consider using patient preferences in benefit-risk assessment? PharmacoEconomics, 32(1), 1–4.PubMed
33.
go back to reference McNeil, D. E., Davis, C., Jillapalli, D., Targum, S., Durmowicz, A., & Coté, T. R. (2010). Duchenne muscular dystrophy: Drug development and regulatory considerations. Muscle and Nerve, 41(6), 740–745.PubMed McNeil, D. E., Davis, C., Jillapalli, D., Targum, S., Durmowicz, A., & Coté, T. R. (2010). Duchenne muscular dystrophy: Drug development and regulatory considerations. Muscle and Nerve, 41(6), 740–745.PubMed
34.
go back to reference Peay, H. L., Hollin, I. L., Fischer, R., & Bridges, J. F. P. (2014). A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clinical Therapeutics, 36(5), 624–637.PubMed Peay, H. L., Hollin, I. L., Fischer, R., & Bridges, J. F. P. (2014). A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clinical Therapeutics, 36(5), 624–637.PubMed
35.
go back to reference Peay, H. L., Sheffer, H., & Tibben, A. (2013). Expectations and decision making in clinical trials for Duchenne and Becker muscular dystrophy. In 18th international congress of the world muscle society, Asilomar. Peay, H. L., Sheffer, H., & Tibben, A. (2013). Expectations and decision making in clinical trials for Duchenne and Becker muscular dystrophy. In 18th international congress of the world muscle society, Asilomar.
36.
go back to reference Finn, A., & Louviere, J. J. (1992). Determining the appropriate response to evidence of public concern: The case of food safety. Journal of Public Policy and Marketing, 11(2), 12–25. Finn, A., & Louviere, J. J. (1992). Determining the appropriate response to evidence of public concern: The case of food safety. Journal of Public Policy and Marketing, 11(2), 12–25.
37.
go back to reference Marley, A. A., & Louviere, J. J. (2005). Some probabilistic models of best, worst, and best-worst choices. Journal of Mathematical Psychology, 49(6), 464–480. Marley, A. A., & Louviere, J. J. (2005). Some probabilistic models of best, worst, and best-worst choices. Journal of Mathematical Psychology, 49(6), 464–480.
38.
go back to reference Flynn, T. N. (2010). Valuing citizen and patient preferences in health: Recent developments in three types of best-worst scaling. Expert Review of Pharmacoeconomics and Outcomes Research, 10(3), 259–267.PubMed Flynn, T. N. (2010). Valuing citizen and patient preferences in health: Recent developments in three types of best-worst scaling. Expert Review of Pharmacoeconomics and Outcomes Research, 10(3), 259–267.PubMed
39.
go back to reference Mühlbacher, A. C., Kaczynski, A., Zweifel, P., & Johnson, F. R. (2015). Experimental measurement of preferences in health and healthcare using best-worst scaling: An overview. Health Economics Review, 6(1), 1–14. Mühlbacher, A. C., Kaczynski, A., Zweifel, P., & Johnson, F. R. (2015). Experimental measurement of preferences in health and healthcare using best-worst scaling: An overview. Health Economics Review, 6(1), 1–14.
40.
go back to reference Flynn, T. N., Louviere, J. J., Peters, T. J., & Coast, J. (2007). Best-worst scaling: What it can do for health care research and how to do it. Journal of Health Economics, 26(1), 171–189.PubMed Flynn, T. N., Louviere, J. J., Peters, T. J., & Coast, J. (2007). Best-worst scaling: What it can do for health care research and how to do it. Journal of Health Economics, 26(1), 171–189.PubMed
41.
go back to reference Flynn, T. N., & Marley, A. (2014). Best-worst scaling: Theory and methods. In S. Hess & A. Daly (Eds.), Handbook of choice modelling (pp. 178–201). Cheltenham: Edward Elgar Publishing Limited. Flynn, T. N., & Marley, A. (2014). Best-worst scaling: Theory and methods. In S. Hess & A. Daly (Eds.), Handbook of choice modelling (pp. 178–201). Cheltenham: Edward Elgar Publishing Limited.
42.
go back to reference Hollin, I. L., Young, C., Hanson, C., Bridges, J., & Peay, H. (2016). Developing a patient-centered benefit-risk survey: A community-engaged process. Value in Health, 19, 751–757.PubMed Hollin, I. L., Young, C., Hanson, C., Bridges, J., & Peay, H. (2016). Developing a patient-centered benefit-risk survey: A community-engaged process. Value in Health, 19, 751–757.PubMed
43.
go back to reference Kuhfeld, W. (2010). Orthogonal arrays [TS-723]. Cary, NC: SAS. Kuhfeld, W. (2010). Orthogonal arrays [TS-723]. Cary, NC: SAS.
44.
go back to reference Youden, W. J. (1940). Experimental designs to increase accuracy of greenhouse studies. Contributions. Boyce Thompson Institute for Plant Research, 11, 219–228. Youden, W. J. (1940). Experimental designs to increase accuracy of greenhouse studies. Contributions. Boyce Thompson Institute for Plant Research, 11, 219–228.
45.
go back to reference Youden, W. J. (1937). Use of incomplete block replications in estimating tobacco-mosaic virus. Contributions from Boyce Thompson Institute, 9(1), 41–48. Youden, W. J. (1937). Use of incomplete block replications in estimating tobacco-mosaic virus. Contributions from Boyce Thompson Institute, 9(1), 41–48.
46.
go back to reference Hauber, A. B., González, J. M., Groothuis-Oudshoorn, C. G., Prior, T., Marshall, D. A., Cunningham, C. et al. (2016). Statistical methods for the analysis of discrete choice experiments: A report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value in Health, 19(4):300–315.PubMed Hauber, A. B., González, J. M., Groothuis-Oudshoorn, C. G., Prior, T., Marshall, D. A., Cunningham, C. et al. (2016). Statistical methods for the analysis of discrete choice experiments: A report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value in Health, 19(4):300–315.PubMed
47.
go back to reference Deal, K. (2014). Segmenting patients and physicians using preferences from discrete choice experiments. The Patient, 7(1), 5–21.PubMed Deal, K. (2014). Segmenting patients and physicians using preferences from discrete choice experiments. The Patient, 7(1), 5–21.PubMed
Metagegevens
Titel
Engaging patients and caregivers in prioritizing symptoms impacting quality of life for Duchenne and Becker muscular dystrophy
Auteurs
Ilene L. Hollin
Holly Peay
Ryan Fischer
Ellen M. Janssen
John F. P. Bridges
Publicatiedatum
26-05-2018
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 9/2018
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-1891-7

Andere artikelen Uitgave 9/2018

Quality of Life Research 9/2018 Naar de uitgave